Canaccord Genuity Q4/11 Orthopedic Preview: Four Movers Over The Next Six Months
Tweet
Share
E-mailGet Alerts ARTC Hot Sheet
Price: $9.97 +0.10%
Rating Summary:
3 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
3 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Canaccord Genuity Q4/11 Orthopedic Preview: Large Joints, Spine, Sports Medicine and Biologics
Analyst, William J. Plovanic, names four companies that are likely to move in the next six months.
ArthroCare (Nasdaq: ARTC)(BUY): looking for DOJ progress and stable financials
MAKO Surgical (Nasdaq: MAKO)(HOLD): preannounces in-line system sales and strong US knee procedure volumes
NuVasive (Nasdaq: NUVA)(BUY): preannounces solid Q4/11; IP dispute weighs the stock down
Orthofix (Nasdaq: OFIX)(BUY): BGS appears stable and ready for 2012 rebound
Mr. Plovanic said, “We continue to view the long-term opportunities positively and firmly believe that in the “new age” of orthopedics there will still be winners and losers, and thus an opportunity for capital gains. Furthermore, while we believe the glory days of the orthopedics industry are unlikely to return, business should improve from current levels when the economy improves, and we note that underlying demographics are favorable. For now, we expect medtech investors to play the waiting game for many of these stocks until consistent growth and subsequent leverage opportunity returns.”
Analyst, William J. Plovanic, names four companies that are likely to move in the next six months.
ArthroCare (Nasdaq: ARTC)(BUY): looking for DOJ progress and stable financials
MAKO Surgical (Nasdaq: MAKO)(HOLD): preannounces in-line system sales and strong US knee procedure volumes
NuVasive (Nasdaq: NUVA)(BUY): preannounces solid Q4/11; IP dispute weighs the stock down
Orthofix (Nasdaq: OFIX)(BUY): BGS appears stable and ready for 2012 rebound
Mr. Plovanic said, “We continue to view the long-term opportunities positively and firmly believe that in the “new age” of orthopedics there will still be winners and losers, and thus an opportunity for capital gains. Furthermore, while we believe the glory days of the orthopedics industry are unlikely to return, business should improve from current levels when the economy improves, and we note that underlying demographics are favorable. For now, we expect medtech investors to play the waiting game for many of these stocks until consistent growth and subsequent leverage opportunity returns.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades John B. Sanfilippo & Son, Inc. (JBSS) to Buy
- NetEase.com (NTES) PT Raised to $168 at Goldman Sachs
- Deutsche Bank Starts Ardagh Metal Packaging S.A. (AMBP) at Hold
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
